Atlanta-based Emory Orthopaedics & Spine Center earned a $13 million grant from The Marcus Foundation for a multicenter clinical trial to evaluate stem cell treatments for osteoarthritis.
Biologics
Bone Biologics completed $5.9 million of financing.
Bioventus entered into a definitive agreement to divest its bone morphogenetic protein development program to a new Viscogliosi Brothers company.
Ortho Regenerative Technologies is an orthopedic biotechnology company developing novel therapeutic tissue repair devices for sports medicine surgeries.
Here are 23 study developments in spine and orthopedic biologics for 2018 so far:
Advertisement
AlloSource is the world's largest processor of cellular bone allografts.
Aziyo Biologics agreed to provide its viable bone matrix product ViBone to medical device company SurGenTec for use with the GraftGun universal graft delivery system.
Cerapedics completed a $22 million financing round to accelerate commercialization of its i-FACTOR Peptide Enhanced Bone Graft for degenerative disc disease.
The global spine biologics market is forecasted to grow at a 4.4 percent compound annual growth rate to exceed $2.6 billion by 2020, according to a Market Research Engine report.
Huntington, W. Va.-based Marshall Orthopaedics surgeon Chad Lavender, MD, is now performing anterior cruciate ligament repair procedures using a patient's bone marrow.